These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11417484)

  • 21. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs].
    Dassonneville L; Bailly C
    Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two different classes of therapy-related and de-novo acute myeloid leukemia?
    Pedersen-Bjergaard J; Philip P
    Cancer Genet Cytogenet; 1991 Aug; 55(1):119-24. PubMed ID: 1655239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of secondary leukemias.
    Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
    Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
    Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
    Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.
    Silva ML; Land MG; Maradei S; Otero L; Veith M; Brito G; Klumb C; Fernandez T; Pombo-de-Oliveira MS
    Cancer Genet Cytogenet; 2002 May; 135(1):101-2. PubMed ID: 12072208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
    J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
    Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich EJ; Keating M; Pierce S; Estey E
    Leukemia; 1994 Dec; 8(12):2174-8. PubMed ID: 7808007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia.
    Zompi S; Viguié F
    Leuk Lymphoma; 2002 Feb; 43(2):275-80. PubMed ID: 11999558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy of secondary leukemias.
    Visani G; Pagano L; Pulsoni A; Tosi P; Piccaluga PP; Pastano R; Grafone T; Malagola M; Isidori A; Tura S
    Leuk Lymphoma; 2000 May; 37(5-6):543-9. PubMed ID: 11042514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
    Snijder S; Mellink CH; van der Lelie H
    Cancer Genet Cytogenet; 2008 Jan; 180(2):149-52. PubMed ID: 18206542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
    Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
    Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
    Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ
    Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
    Todisco E; Testi AM; Avvisati G; Moleti ML; Cedrone M; Cimino G; Mancini F; Amadori S; Mandelli F
    Leukemia; 1995 Sep; 9(9):1583-5. PubMed ID: 7658728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
    McHayleh W; Sehgal R; Redner RL; Raptis A; Agha M; Natale J; Luong TM; Schlesselman JJ; Foon KA; Boyiadzis M
    Leuk Lymphoma; 2009 Nov; 50(11):1848-53. PubMed ID: 19860628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.